Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
|Articles|September 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 9
- Volume 15
- Issue 9
Phase I/II Trial of AGS-003
Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.
Advertisement
DURHAM, North CarolinaArgos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.
Articles in this issue
about 20 years ago
Exjade Gains Approval in EUabout 20 years ago
President's Cancer Panel Assesses Progress in Two Areasabout 20 years ago
Cognitive Rx Reduces Depression in Breast Ca Ptsabout 20 years ago
Nurses Develop Evidence-Based Guidelines for Mucositisabout 20 years ago
Anastrozole Therapy for Breast Cancer Affects Bone Healthabout 20 years ago
Is Demand for Trial Subjects Outpacing Supply?about 20 years ago
Postchemo Disappearance of Liver Mets Doesn't Mean Cureabout 20 years ago
Aromasin-Related Bone Loss Affected by Vitamin D LevelsAdvertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5